We sought to determine the efficacy of high-dose liraglutide (3.0 mg once daily) in patients with prior bariatric surgery.
Objective: To identify predictors for achieving a BMI of less than 30 after bariatric surgery.
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging...
Objective: Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of glucagon-like peptide-1, is indicated ...
New data from the phase IIIa SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and...
Xultophy is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
Novo Nordisk announced headline results from the second and final Phase IIIa trial with Victoza (liraglutide) as adjunct therapy to...
This document is about guidance for commissioning reconstructive procedures, post massive weight loss and is based on the best available evidence.
Novo Nordisk reported new data from the phase IIIa SCALE Obesity and Prediabetes trial at Obesity Week 2014, the 2nd...